natgillin/translations-raw huggingface dataset:
Clinical experience in patients aged above 65 years is limited.
Kliničko iskustvo s bolesnicima u dobi iznad 65 godina je ograničeno.
Clinical experience in patients with moderate renal impairment (creatinine clearance 30 to 50 ml/min) is very limited (see section 5.2).
Kliničko iskustvo u bolesnika s umjerenim oštećenjem bubrega (klirens kreatinina 30 do 50 ml/min) vrlo je oskudno (vidjeti dio 5.2).
Clinical experience in patients with percent predicted FEV1 (ppFEV1) <40 is limited and additional monitoring of these patients is recommended during initiation of therapy (see section 4.8).
Zbog ograničenog kliničkog iskustva s bolesnicima u kojih je postotak predviđenog FEV1 (ppFEV1) < 40, preporučuje se dodatno praćenje tih bolesnika za vrijeme započinjanja terapije (vidjeti dio 4.8).
Clinical experience is limited in patients with body weight <50 kg.
Ograničeno je kliničko iskustvo u bolesnika tjelesne težine <50 kg.
Clinical experience of MabThera concentrate for solution for infusion in Non-Hodgkin’s lymphoma
Klinička iskustva s primjenom MabThera koncentrata za otopinu za infuziju u liječenju ne-Hodgkinova limfoma
Clinical experience of MabThera subcutaneous formulation in Non-Hodgkin’s lymphoma
Klinička iskustva s primjenom lijeka MabThera u formulaciji za supkutanu primjenu u liječenju ne-Hodgkinova limfoma
Clinical experience with concomitant administration of bosentan with warfarin in patients with pulmonary arterial hypertension did not result in clinically relevant changes in International Normalized Ratio (INR) or warfarin dose (baseline versus end of the clinical studies).
Tijekom kliničkih studija istodobne primjene bosentana i varfarina u bolesnika s plućnom arterijskom hipertenzijom nije došlo do klinički značajnih promjena internacionalnog normaliziranog omjera (INR) ili doze varfarina (između početne i krajnje vrijednosti u kliničkim studijama).
Clinical experience with Fluenz is relevant to Fluenz Tetra because both vaccines are manufactured using the same process and have overlapping compositions.
Kliničko iskustvo s cjepivom Fluenz relevantno je za Fluenz Tetra, jer su oba cjepiva proizvedena korištenjem istog procesa te im se sastavi preklapaju.
Clinical experience with fosamprenavir boosted with ritonavir is mainly based on two open label studies one in antiretroviral naïve patients (study ESS100732), and one study in antiretroviral experienced patients (study APV30003).
Kliničko iskustvo s fosamprenavirom pojačanim ritonavirom uglavnom se temelji na 2 otvorena ispitivanja: prvom, na bolesnicima koji nisu primali raniju terapiju antiretrovirusnim lijekovima (ispitivanje ESS100732) i drugom, na bolesnicima koji su primali raniju terapiju antiretrovirusnim lijekovima (ispitivanje APV30003).
Clinical experience with immunoglobulins suggests however that no harmful effects on the neonate are to be expected.
Međutim, kliničko iskustvo s imunoglobulinima ukazuje na to da ne treba očekivati štetne učinke na novorođenčad.
Clinical experience with immunoglobulins suggests that no harmful effects on fertility are to be expected.
Klinička iskustva s imunoglobulinom upućuju na to da nema očekivanih štetnih učinaka na plodnost.
Clinical experience with immunoglobulins suggests that no harmful effects on the course of pregnancy, or on the foetus or the neonate are to be expected.
Klinička iskustva s imunoglobulinom upućuju na to da nema očekivanih štetnih učinaka na tijek trudnoće, ili na fetus i novorođenče.
Clinical experience with ipilimumab- associated endocrinopathy is limited.
Kliničko iskustvo s endokrinopatijama povezanima s ipilimumabom je ograničeno.
Clinical experience with the combination of abacavir and lamivudine as a once daily regimen is mainly based on four studies in treatment-naïve subjects, CNA30021, EPZ104057 (HEAT study), ACTG5202, and CNA109586 (ASSERT study) and two studies in treatment-experienced subjects, CAL30001 and ESS30008.
Kliničko iskustvo sa kombinacijom abakavira i lamivudina u jednodnevnom režimu se većinom bazira na četiri ispitivanja na prethodno neliječenim bolesnicima, CNA30021, EPZ104057 (HEAT ispitivanje), ACTG5202, te CNA109586 (ASSERT ispitivanje) i dva ispitivanja u prethodno liječenim bolesnicima CAL30001 i ESS30008.
Clinical experience: the demonstration of benefit is based on histological, virological, biochemical, and serological responses after 48 weeks of treatment in active-controlled clinical trials of 1,633 adults with chronic hepatitis B infection, evidence of viral replication and compensated liver disease.
Kliničko iskustvo: korist od liječenja pokazala se na temelju histoloških, viroloških, biokemijskih i seroloških odgovora nakon 48 tjedana liječenja u aktivno kontroliranim kliničkim ispitivanjima 1633 odrasla bolesnika s infekcijom kroničnim hepatitisom B, dokazom umnažanja virusa i kompenziranom bolešću jetre.
Clinical factors, evaluation of any laboratory and imaging investigations could be included as part of this re-consideration.
Kao dio ovog ponovnog razmatranja mogu se uključiti klinički čimbenici i ocjenjivanje laboratorijskih pretraga kao i pretraga oslikavanja.
Clinical failure, no. (%)
Klinički neuspjeh, br. (%)
clinical findings also
nalazi također ukazuju na
Clinical follow up details
Podatke o kliničkom praćenju
Clinical Global Impressions of Change (CGI-c)
Klinički opći dojam promjene (CGI-c)
Clinical guidelines describing the aggressive management of CTID includes specific recommendations on patient communication and awareness, recognition of early warning signs, use of anti-diarrhoeals and antibiotics, changes in fluid intake and diet, and need for hospitalisation (see sections 4.2 and 4.8).
Kliničke smjernice koje propisuju agresivno zbrinjavanje CTID uključuju specifične preporuke o komunikaciji i osviještenosti bolesnika, prepoznavanju ranih znakova upozorenja, korištenju antidijaroika i antibiotika, promjenama u uzimanju tekućine i prehrani te o potrebi za hospitalizacijom (vidjeti dio 4.2 i 4.8).
Clinical improvement including onset of action within 2 weeks with Enbrel 25 mg was similar to that seen in the previous trials, and was maintained for up to 24 months.
Kliničko poboljšanje, uključujući početak djelovanja Enbrela u dozi od 25 mg unutar razdoblja od 2 tjedna, bilo je slično onome zabilježenom u prethodnim ispitivanjima te se održalo tijekom sljedeća 24 mjeseca.
Clinical improvement measured by sPGA, PASI-50 and PASI-90 responses were also demonstrated at Week 16.
U 16. tjednu pokazalo se također kliničko poboljšanje mjereno kao rezultat sPGA, PASI-50 i PASI-90.
Clinical improvement with Reconcile is expected within 1 or 2 weeks.
Klinička poboljšanja uz Reconcile očekuje se unutar 1 do 2 tjedna.
Clinical improvement with Reconcile is expected within 1 to 2 weeks.
Klinička poboljšanja uz Reconcile očekuju se u roku od 1 do 2 tjedna.
Clinical interaction studies with diazepam and non- steroidal anti-inflammatory medicinal products have not been carried out.
Klinička ispitivanja interakcija s diazepamom i nesteroidnim protuupalnim lijekovima nisu provedena.
Clinical interaction studies with diazepam and non-steroidal anti- inflammatory medicinal products have not been carried out.
Klinička ispitivanja interakcija s diazepamom i nesteroidnim protuupalnim lijekovima nisu provedena.
Clinical isolates of HIV-2 demonstrated EC50 values in the range of 0.3-2.4 nM.
U kliničkim izolatima HIV-2 vrijednosti EC50 kretale su se u rasponu od 0,3 do 2,4 nM.
Clinical judgement of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment.
Liječnik koji provodi liječenje mora na temelju svoga stručnog kliničkog mišljenja odrediti plan liječenja za svakog bolesnika pojedinačno na osnovi individualne procjene koristi i rizika.
Clinical judgment should be exercised when administering Mozobil to patients with peripheral blood neutrophil counts above 50 x 109/L.
Prije primjene lijeka Mozobil u bolesnika koji u perifernoj krvi imaju više od 50 x 109 neutrofila/L potrebna je odgovarajuća klinička procjena.
Clinical Management:
Kliničko zbrinjavanje:
Clinical manifestations of anaphylaxis may appear similar to clinical manifestations of infusion associated reactions, but would tend to be more severe or potentially life- threatening.
Kliničke manifestacije anafilaksije mogu se pojaviti slično kao kliničke manifestacije reakcija povezanih s infuzijom, no imaju tendenciju biti teže ili potencijalno opasne po život.
Clinical monitoring and
kliničko praćenje i
Clinical monitoring and
Preporučuje se kliničko
Clinical monitoring and dose adjustment may be required for levothyroxine.
Nije potrebno prilagođavati dozu za diazepam; primijeniti veću dozu ako je to klinički indicirano.
Clinical monitoring and dose adjustment maybe needed for s-mephenytoin.
praćenje i prilagodba doze
Clinical monitoring is
Preporučeno je kliničko praćenje kada se
Clinical monitoring is
Preporučuje
Clinical monitoring is
Preporučuje se kliničko praćenje kada se
Clinical monitoring is recommended and a dose decrease may be necessary when these agents are co-administered with Genvoya.
U slučaju istodobne primjene lijeka Genvoya i ovih lijekova preporučuje se klinički nadzor i može biti potrebno smanjenje doze.
Clinical monitoring is recommended and a dose decrease may be necessary when these agents are co-administered with Stribild.
Stribilda i ovih lijekova preporučuje se klinički nadzor i može biti potrebno smanjenje doze.
Clinical monitoring is recommended and a dose reduction may be necessary when these beta-blockers are co-administered with Tybost.
U slučaju istovremene primjene lijeka Tybost i ovih beta-blokatora preporučuje se klinički nadzor i može biti potrebno smanjenje doze.
Clinical monitoring is recommended and an increase of olanzapine dose may be considered if necessary (see section 4.5)
Preporučuje se klinički nadzor, a po potrebi se može razmotriti i povećanje doze olanzapina (vidjeti dio 4.5).
clinical monitoring is recommended for
kliničko praćenje itrakonazola, posakonazola i
Clinical monitoring is recommended for patients with ClCr < 90 mL/min.
Klinički nadzor preporučuje se za pacijente s vrijednošću ClCr < 90 ml/min.
Clinical monitoring is recommended for patients with CrCl < 90 mL/min.
Preporučuje se kliničko praćenje pacijenata s CrCl < 90 ml/min.
Clinical monitoring is recommended upon co- administration with EVOTAZ.
Preporučuje se kliničko praćenje nakon istodobne primjene s lijekom EVOTAZ.
Clinical monitoring is recommended upon co-administration with Tybost.
Klinički nadzor se preporuča prilikom istovremene primjene lijeka Tybost.
Clinical monitoring is recommended when co-administering boosted PREZISTA with corticosteroids.
Preporučeno je kliničko praćenje pri istodobnoj primjeni pojačane PREZISTE s kortikosteroidima.
Clinical monitoring is recommended when co-administering PREZISTA with low dose ritonavir with corticosteroids.
Preporučeno je kliničko praćenje pri istodobnoj primjeni PREZISTE s niskom dozom ritonavira s kortikosteroidima.
Clinical monitoring is recommended when dabigatran is co-administered with P-gp inhibitors.
Klinički nadzor preporučuje se kada se dabigatran istodobno primjenjuje s inhibitorima P-gp.
Clinical monitoring is recommended when dabigatran is co-administered with P-gp inhibitors.
Klinički nadzor preporučuje se kada se dabigatran istovremeno primjenjuje s inhibitorima P-gp.
Clinical monitoring is recommended when dabigatran is co-administered with P-gp inhibitors.
Preporučuje se klinički nadzor kod istovremene primjene dabigatrana s inhibitorima P-gp.
Clinical monitoring may be needed upon co- administration with EVOTAZ.
Možda će biti potrebno kliničko praćenje nakon istodobne primjene s lijekom EVOTAZ.
clinical monitoring of
rifapentinom jer
Clinical monitoring of antiviral efficacy is recommended when these medicines are concomitantly administered with Kaletra.
Pri primjeni ovih lijekova istodobno s lijekom Kaletra preporučuje se kliničko praćenje liječenja i nuspojava.
Clinical monitoring of patients is recommended.
nadzor bolesnika.
Clinical monitoring of the child condition, and dose readjustment, need to be performed at least monthly.
Kliničko praćenje stanja djeteta i ponovno prilagođavanje doze mora se provesti najmanje mjesečno.
Clinical monitoring of therapeutic
Preporučeno je kliničko praćenje
Clinical monitoring of therapeutic and adverse effects is recommended when these medicinal products are concomitantly administered with Stribild.
Stribilda i ovih lijekova preporučuje se klinički nadzor terapijskih učinaka i nuspojava.
Clinical monitoring of therapeutic effect and adverse events is
terapijskih učinaka i nuspojava pri
Clinical monitoring of therapeutic effect and adverse reactions is recommended.
Preporučuje se kliničko praćenje terapijskog učinka i nuspojava.
Clinical monitoring should be made upon co-administration with Stribild.
Klinički nadzor mora se primijeniti prilikom istovremene primjene Stribilda.
Clinical outcomes - gout flares requiring treatment
Klinički ishodi – akutni napadaji gihta koja zahtijevaju liječenje
Clinical outcomes - tophus resolution and reduction
Klinički ishodi – povlačenje i smanjenje tofa
Clinical Outcomes: proportion of patients requiring treatment for a gout flare
Klinički ishodi: udio bolesnika koji zahtijevaju liječenje akutnog napada gihta
Clinical Parameters
Klinički parameteri
CLINICAL PARTIC ULARS
KLINIČKI PODACI
CLINICAL PARTICULARS
CLINICAL PARTICULARS KLINIČKE POJEDINOSTI
CLINICAL PARTICULARS
KLINIĈKI PODACI
CLINICAL PARTICULARS
KLINIČKA SVOJSTVA
Clinical recommendation
Klinička preporuka o istodobnoj
Clinical recommendation
Za erektilnu disfunkciju:
Clinical recommendation concerning co-administration with lopinavir/ritonavir
Klinička preporuka o istodobnoj
Clinical recommendation concerning co-administration with lopinavir/ritonavir
Klinička preporuka o istodobnoj primjeni s lopinavirom/ritonavirom
Clinical recommendation concerning co-administration with lopinavir/ritonavir
produljene istodobne primjene s
Clinical relevance of this observation is unknown, since at least 99.4% of subjects (N=178) had rSBA titres ≥ 8 for each group (A, C, W-135, Y) (see section 4.4).
Klinička važnost ovog zapažanja nije poznata budući da je barem 99,4% osoba (N=178) imalo rSBA titar ≥ 8 za svaku grupu (A, C, W-135, Y) (vidjeti dio 4.4).
Clinical relevance of this observation is unknown, since at least 99.4% of subjects (N=178) had rSBA titres ≥8 for each group (A, C, W-135, Y) (see section 4.4).
Klinička važnost ovog zapažanja nije poznata budući da je barem 99,4% osoba (N=178) imalo rSBA titar ≥ 8 za svaku grupu (A, C, W-135, Y) (vidjeti dio 4.4).
Clinical relevance of this observation is unknown.
Nije poznata klinička važnost tog zapažanja.
Clinical relevance unknown.
Klinički značaj nije poznat.
Clinical relevance unknown.
mehanizam nije poznat
Clinical remission (defined as Mayo score ≤ 2 with no subscore > 1) was assessed at Week 8.
Klinička remisija (definirana kao Mayo rezultat ≤ 2 bez podrezultata > 1) ocjenjivala se u osmom tjednu.
Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from Baseline) rates are presented in Table 14.
Stope kliničke remisije i kliničkog odgovora (definirano kao smanjenje PCDAI rezultata za barem 15 bodova od početne vrijednosti) prikazane su u Tablici 14.
Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from Baseline) rates are presented in Table 19.
Stope kliničke remisije i kliničkog odgovora (definirano kao smanjenje PCDAI rezultata za barem 15 bodova od početne vrijednosti) prikazane su u Tablici 19.
Clinical remission and clinical response (defined as reduction in PCDAI score of at least 15 points from Baseline) rates are presented in Table 21.
Stope kliničke remisije i kliničkog odgovora (definirano kao smanjenje PCDAI rezultata za barem 15 bodova od početne vrijednosti) prikazane su u Tablici 21.
Clinical remission at week 30a
Klinička remisija u 30. tjednua
Clinical remission at week 30a
Klinička remisija u 8. tjednua
Clinical remission at Week 30a 13.1%
Klinička remisija u 30. tjednua
Clinical remission at week 8a
Klinička remisija u 8. tjednua
Clinical remission at Week 8a 10.2%
Klinička remisija u 8. tjednua
Clinical Remission in patients:
Klinička remisija u bolesnika:
Clinical remission is defined as CDAI score < 150; Clinical response is defined as reduction in CDAI of at least 100 points or being in clinical remission
Klinička remisija je definirana kao CDAI skor < 150; Klinički odgovor je definiran kao smanjenje u CDAI skoru za barem 100 bodova ili bivanje u kliničkoj remisiji
Clinical remission rate in GEMINI II at Week 6 was 10% (difference from placebo 2%, 95% CI: -6, 10) when administered without corticosteroids compared to 20% (difference from placebo 14%, 95% CI: -1, 29) when administered with concomitant corticosteroids.
Stopa kliničke remisije u ispitivanju GEMINI II u 6. tjednu iznosila je 10% (razlika u odnosu na placebo bila je 2%, 95%-tni interval pouzdanosti: -6, 10) kad se terapija primjenjivala bez kortikosteroida u usporedbi sa 20% (razlika u odnosu na placebo 14%, 95%-tni interval pouzdanosti: -1, 29) uz istovremenu primjenu kortikosteroida.
Clinical remission, Week 6
Klinička remisija, 6. tjedan
Clinical Remission, week 8
Klinička remisija, 8. tjedan
Clinical remission§
Klinička remisija§
Clinical resistance in monotherapy studies in nucleoside naïve patients: In patients receiving adefovir dipivoxil monotherapy (HBeAg negative study) the cumulative probability of developing adefovir-associated resistance mutations was 0 %, 3 %, 11 %, 18 % and 29 % at 48, 96, 144, 192 and 240 weeks respectively.
Klinička rezistencija u ispitivanjima monoterapije u pacijenata koji prethodno nisu primali nukleozide: U pacijenata koji su primali monoterapiju adefovirdipivoksilom (ispitivanja s HBeAg negativnim pacijentima) kumulativna vjerojatnost razvoja mutacija povezanih s rezistencijom na adefovir bile su 0% u 48. tjednu, 3% u 96., 11% u 144., 18% u 192. i 29% u
Clinical Response (100 point), week 6
Klinički odgovor (100 bodova), 6. tjedan
Clinical Response (100 point), week 8
Klinički odgovor (100 bodova), 8. tjedan
Clinical response (Entrainment + N24CRS
Klinički odgovor (usklađivanje + N24CRS
Clinical response and remission were significant as early as week 3 in ustekinumab treated patients and continued to improve through week 8.
Klinički odgovor i remisija bili su značajni već u 3. tjednu u bolesnika liječenih ustekinumabom i nastavili su se poboljšavati do 8. tjedna .
Clinical Response at Follow-up (day 12-14), by Analysis population
Klinički odgovor na kontrolnom pregledu (12. - 14. dan), prema analiziranoj populaciji
Clinical response at week 16 in studies ESTEEM 1 and ESTEEM 2 (FAS a, LOCFb)
Klinički odgovor u 16. tjednu u ispitivanjima ESTEEM 1 i ESTEEM 2 (FASa LOCFb)
Clinical response at Week 30a
Klinički odgovor u 30. tjednua
Clinical response at week 30a
Održani odgovor (klinički odgovor i u
Clinical response at week 8 was similar between those with or without concomitant immunomodulator use at baseline.
8. tjednu bio je sličan u bolesnika koji su na početku ispitivanja istodobno uzimali imunomodulatore i onih koji nisu.
Clinical response at Week 8a
Klinički odgovor u 8. tjednua
Clinical response in sleep-wake amount and timing measures
Klinički odgovor u mjerama količine i vremena nastupa budnosti i spavanja
Clinical response is decrease from baseline in Mayo score ≥ 3 points and ≥ 30% plus a decrease in the rectal bleeding subscore [RBS] ≥ 1 or an absolute RBS of 0 or 1;
Klinički odgovor je postignut ako je ostvareno smanjenje Mayo rezultata u odnosu na početne vrijednosti od ≥ 3 boda i ≥ 30%, uz smanjenje podrezultata rektalnog krvarenja [engl. rectal bleeding subscore, RBS] od ≥1 ili apsolutni RBS od 0 ili 1;
Clinical response is decrease from baseline in Mayo score ≥3 points and ≥30% plus a decrease in the rectal bleeding subscore [RBS] ≥1 or an absolute RBS of 0 or 1;
Klinički odgovor je postignut ako je ostvareno smanjenje Mayo rezultata u odnosu na početne vrijednosti od ≥ 3 boda i ≥ 30%, uz smanjenje podrezultata rektalnog krvarenja [engl. rectal bleeding subscore, RBS] od ≥1 ili apsolutni RBS od 0 ili 1;
Clinical Response5
Klinički odgovor5
Clinical Responsea
(0,008)
Clinical Responsea
Klinički odgovora
Clinical responses among nr-AxSpa patients who received Enbrel were apparent at the time of the first visit (2 weeks) and were maintained through 2 years of therapy.
Klinički odgovori među bolesnicima s aksijalnim spondiloatrtitisom bez radiografskog dokaza koji su primali Enbrel bili su uočljivi u vrijeme prvog posjeta (2 tjedna) i održani su kroz 2 godine liječenja..
Clinical results
Klinički podaci
Clinical safety data with Triumeq are limited.
Klinički podaci o sigurnosti lijeka Triumeq su ograničeni.
clinical setting.
primjene u kliničkom
Clinical significant respiratory depression may occur with fentanyl, and patients must be observed for these effects.
Fentanil može izazvati klinički značajnu depresiju disanja, te se kod bolesnika mora obratiti pažnju na takvo djelovanje.
Clinical signs / pathology
Klinički simptomi/patologija
Clinical signs evident after large single doses or repeated lower doses were similar in all species studied and included tremors, convulsions, ataxia, dyspnoea, dilated pupils, prostration, abnormal vocalization, increased respiration, and excess salivation.
Klinički znakovi očiti nakon velike pojedinačne doze ili ponavljane niže doze su bili slični u svim ispitivanim vrstama, a uključili su tremor, konvulzije, ataksiju, dispneju, proširenje zjenica, prostraciju, abnormalnu vokalizaciju, ubrzano disanje i prekomjernu salivaciju.
Clinical signs including vomiting on first administration, excess salivation and watery faeces have been observed when the product has been administered at doses in excess of 20 mg/kg.
Klinički znaci koji uključuju povraćanje kod prve primjene, pojačano slinjenje i mekani feces primijećeni su kada se proizvod daje u dozi većoj od 20 mg/kg.
Clinical signs of depression, lethargy, vomiting, diarrhoea or weakness: Increase the glucocorticoid dose.
Klinički znaci depresije, letargije, povraćanja, proljeva ili malaksalosti: povećajte dozu glukokortikoida.
Clinical signs of polyuria/polydipsia: Decrease the glucocorticoid dose first.
Klinički znaci poliurije/polidipsije: prvo smanjite dozu glukokortikoida.
Clinical signs of porcine proliferative enteropathy (ileitis)
kliničkih znakova svinjske proliferativne enteropatije (ileitisa)
Clinical signs such as temporary mild behavioural disturbances can uncommonly be observed after application of ECOPORC SHIGA.
Klinički znakovi poput privremenih blagih poremećaja u ponašanju rijetko se primjećuju nakon primjene cjepiva ECOPORC SHIGA.
Clinical SO 1
Kliničko SO 1
clinical state of the subject.
kliničko stanje bolesnika.
Clinical studies
Klinička ispitivanj
Clinical studies 201 and 202 indicate that the combination of IT ziconotide and IT morphine may effectively reduce pain and decrease systemic opioid use over a sustained period of time for patients whose pain was inadequately controlled with their maximum tolerated dose of IT ziconotide (median
Klinička ispitivanja 201 i 202 pokazuju da kombinacija intratekalnog zikonotida i intratekalnog morfina može učinkovito smanjiti bol te tijekom kontinuiranog razdoblja smanjiti sistemsku primjenu opioida u bolesnika u kojih bol nije bila odgovarajuće kontrolirana primjenom maksimalno podnošljive doze samo intratekalnog zikonotida (medijan 8,7 μg/dan, srednja vrijednost
Clinical studies demonstrated that the immune responses and the safety profiles of the co-administered vaccines were unaffected, with the exception of the inactivated poliovirus type 2 response, for which inconsistent results were observed across studies (seroprotection ranging from 78% to 100%).
Klinička ispitivanja su pokazala da imunološki odgovori i sigurnosni profili istodobno primjenjivanih cjepiva nisu promijenjeni, s iznimkom imunološkog odgovora na inaktivirani poliovirus tipa 2, za koji su primijećeni nekonzistentni rezultati tijekom ispitivanja (seroprotekcija koja varira od 78% do 100%).